Roger R. Beerli serves on NBE-Therapeutics’ Scientific Advisory Board since January 2022. Roger was part of NBE-Therapeutics’ management between April 2013 and December 2021 and served as NBE’s Chief Scientific Officer from March 2015. Prior to his engagement with NBE-Therapeutics, he has led therapeutic antibody development activities at Cytos Biotechnology AG, Switzerland, and later at Intercell AG, Austria. Roger has 20 years of experience in the discovery, engineering and preclinical development of antibody-based therapeutics.
Roger studied molecular biology at the University of Zurich, Switzerland, and obtained his PhD for work at the Novartis-associated Friedrich Miescher Institute in Basel, Switzerland, for research on ErbB receptor tyrosine kinases, for which he was awarded the Edmond Fischer Prize. He performed his postdoctoral research at The Scripps Research Institute in La Jolla, California, USA, in the lab of the late Prof. Dr. Carlos F. Barbas III. Here he specialized in phage display for protein and antibody engineering and was among the first to demonstrate artificial regulation of endogenous genes using engineered zinc finger-based transcription factors.
Roger has published widely in the areas of protein discovery, protein engineering and antibody development, and he is co-inventor on numerous patents and patent applications.